Skip to main content

Table 1 Baseline characteristics of 91 DME patients

From: Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab

Characteristic

Age (years)

54 [47–61]

Male sex (%)

57 (62.6)

Duration of DM (years)

6.00 [5.00–8.00]

SBP (mmHg)

135 [121–147]

DBP (mmHg)

83 [72–90]

HbA1c (%)

7.24 ± 1.56

TC (mmol/L)

5.06 ± 1.21

TG (mmol/L)

1.52 [0.94–2.03]

HDL (mmol/L)

1.15 [0.90–1.42]

LDL (mmol/L)

2.73 [2.24–3.39]

Scr

86.90 [62.70–117.00]

BUN

6.00 [5.10–8.30]

Mean BCVA (letter score)

45.99 ± 12.74

Mean CRT (μm)

484.65 ± 113.08

WBC (× 109/L)

5.93 [4.88–7.48]

Neutrophils (×109/L)

3.51 [2.73–4.84]

Monocytes (× 109/L)

0.40 [0.30–0.48]

Platelets (× 109/L)

186.00 [140.00–237.00]

Lymphocytes (× 109/L)

1.62 [1.29–1.90]

NLR

2.27 [1.72–2.93]

MLR

0.24 [0.18–0.30]

PLR

114.37 [86.02–146.74]

  1. Data are expressed as mean (SD), median (inter-quartile range), or percentage
  2. DM diabetes mellitus, SBP systolic blood pressure, DBP diastolic blood pressure, WBC white blood cell, HbA1c Hemoglobin A1c, TC total cholesterol, TG triglycerides, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, Scr serum creatinine, BUN blood urea nitrogen, BCVA best-corrected visual acuity, CRT central retinal thickness, WBC white blood cell, NLR neutrophil-to-lymphocyte ratio, MLR monocyte-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio.